{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"8.540","floor":"7.760"},"ipodate":{"start":"2019-06-13 00:00:00","end":"2019-06-18 00:00:00"},"minimumcapital":"17252.11","subscribed":"99.26","marketcap":"203.32億","H_marketcap":"--","pe":"107.69","codesrate":"65.00","link":"https://staticpdf.iqdii.com/stockdata/notice/01951/2019/LTN20190613012_C.pdf","ipopricing":"8.540","resultdate":"2019-06-24 00:00:00","enddate":"2019-06-18 00:00:00","listeddate":"2019-06-25 00:00:00","issuenumber":"35712.40萬","issuenumberhK":"14285.20萬","issuenumberother":"21427.20萬","grayprice":"9.83","sponsors":"摩根士丹利亞洲有限公司,中信里昂證券資本市場有限公司","raisemoney":"280810.00萬","use":"1、約25.0%或702.0百萬港元將用于拓展及升級我們中國網絡的現有輔助生殖醫療機構及招聘醫療專業人士；\n2、約20.0%或561.6百萬港元將用于我們目前并無經營的中國省份的額外輔助生殖醫療機構潛在收購；\n3、約10.0%或280.8百萬港元將用于投資研發以改善整體表現及維持我們ART的前沿地位；\n4、約20.0%或561.6百萬港元將用于輔助生殖服務服務鏈的輔助生殖服務提供商及業務潛在收購；\n5、約15.0%或421.2百萬港元將用于改善品牌專注度以及中國及美國對輔助生殖服務的整體專注；\n6、約10.0%或280.8百萬港元將用于營運資金及一般企業用途。","shares":2000,"leadagent":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,花旗環球金融亞洲有限公司,招商證券(香港)有限公司,招銀國際融資有限公司,中信建投(國際)融資有限公司,農銀國際融資有限公司,工銀國際融資有限公司,華泰金融控股(香港)有限公司,未來資產證券(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,花旗環球金融亞洲有限公司,招商證券(香港)有限公司,招銀國際融資有限公司,中信建投(國際)融資有限公司,農銀國際融資有限公司,工銀國際融資有限公司,華泰金融控股(香港)有限公司,未來資產證券(香港)有限公司","coordinator":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,花旗環球金融亞洲有限公司,招商證券(香港)有限公司","firstDayOpen":"9.90","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E01951","name":"錦欣生殖","fullname":"錦欣生殖醫療集團有限公司"},"institutioninfo":{"principaloffice":"中國四川省成都市錦江區靜沙北路301號","registrars":"香港中央證券登記有限公司","registrarstel":"(852)2862 8628","chairman":"王彬","secretary":"劉竑琨,梁雪穎","telephone":"(86)400 613 9696","substantialshareholders":"Jinxin Fertility BVI(21.10%),Amethyst Gem(18.77%),HRC Investment(15.15%),Jinxin Global BVI(5.50%)","principalactivities":"公司是中美領先的輔助生殖服務供貨商。","website":"www.jxr-fertility.com"},"managerinfo":[{"managername":"王彬","post":"主席兼非執行董事","rankno":1},{"managername":"鐘影","post":"首席執行官兼執行董事","rankno":2},{"managername":"嚴曉晴","post":"高級副總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"Hillhouse Funds","shareholding":"64,256,000.0","percentage":17.99,"ReleaseDate":"2019-12-25 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"Worldwide Healthcare Trust PLC","shareholding":"27,538,000.0","percentage":7.71,"ReleaseDate":"2019-12-25 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"Ally Bridge LB Healthcare Master Fund Limited","shareholding":"27,538,000.0","percentage":7.71,"ReleaseDate":"2019-12-25 00:00:00","relatedparty":"Ally Bridge LB Management Limited","subsidiary":["Ally Bridge LB Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"Cormorant Asset Management, LP","shareholding":"18,358,000.0","percentage":5.14,"ReleaseDate":"2019-12-25 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":38.55},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":9}